Berlato et al. [37] detected abundant CCR4 expression in biopsy samples from advanced ccRCC patients and demonstrated that CCR4 antagonists remodeled the immune infiltration profile, resulting in reduced tumor weight in RCC-bearing mice. The gene discussed is CCR4; the disease is nonpapillary renal cell carcinoma.